Evicenter
MarkdownMedical informationP&T meetings
VK2735

Chronic weight management

Last updated
184 sources

Clinical evidence

SUNRISE-1

27 evidence topics · 13 sources

Objective
Location and study date
Study design
FDA end-of-phase 2 meeting for the oral tablet
Eligibility criteria
Treatment
Study outcomes
Rationale for using percent change in body weight as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Analysis populations

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

SUNRISE-1 had reported no results as of November 2026, and every leaf on disposition, baseline characteristics, efficacy, quality of life, and safety is empty. The design is known only from the ClinicalTrials.gov record, company press releases, an investor presentation, and transcripts of investor calls; no protocol, statistical analysis plan, or peer-reviewed design paper is available.

The registry and the company documents differ on status and on doses. The company announced the program's initiation on October 14, 2026, and its later documents describe the trials as “Underway”, while the registry record still lists the study as “Not yet recruiting” with an estimated start in November 2026. The registry describes the three active arms only as dose levels 1 to 3; the doses of 27.5 mg, 35 mg, and 55 mg are stated in company releases.

The registry record lists one primary outcome and no secondary outcomes, so the responder endpoints and exploratory endpoints (function, metabolic health, mental health, productivity) rest on company documents. The planned enrollment of 560 participants is about 75% smaller than the subcutaneous phase 3 program, a reduction the company attributes to reusing safety data from the subcutaneous trials, which the FDA accepted while noting “risks going from phase II to phase III”. The company states that the doses were chosen in part to lower “the tablet burden” and for gross margin, and gives no exposure-response analysis for them. The FDA's details from the end-of-phase 2 meeting are not public, and the company declined to describe them.